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THE ESTIMATED IMPACT OF IN VITRO BIOMARKERS ON THE COST-
EFFECTIVENESS OF POPULATION-WIDE COLORECTAL CANCER 
SCREENING
Wittenberg GM, Noy K, Dejori M, Fasulo D
Siemens Corporate Research, Princeton, NJ, USA
OBJECTIVES: Most screening options for colorectal cancer (CRC) are invasive and
patient compliance in population wide screening programs is low. Recently, potential
candidates for blood-based biomarker tests for early cancer detection have been
described. Here we perform an extensive cost-effectiveness analysis of integrated 
diagnostic screening workﬂ ows to determine the anticipated impact of incorporating 
two candidate in vitro biomarkers, CCSA-3 immunoassay and SEPT9 epigenetics
testing, on both patient mortality and medical costs. METHODS: Markov Cycle
Tree models were constructed to simulate disease progression and screening for 4
million people, representative of the U.S. population, aging from 50 to 80. Eight 
workﬂ ows were constructed from combinations of Optical Colonoscopy (OC), CT 
Colonography (CTC), Fecal Occult Blood Test (FOBT), Immunoassay (CCSA-3), and
Epigenetics (SEPT9). Kernel density estimation was performed on raw biomarker data 
to generate disease-state probability distributions of biomarker levels for sensitivity 
and speciﬁ city calculations. Finally, we perform sensitivity analysis on the sensitivity 
and speciﬁ city of a generic in vitro diagnostic test. RESULTS: CRC screening work-
ﬂ ows that include initial screening with inexpensive in vitro diagnostic tests given every 
3 years outperform others in both cost and effectiveness. Incremental costs compared 
with No Screening are as follows: OC $1.4B increase, SEPT9 $582M increase, CCSA-
3 $2.8B decrease. Life-years saved: OC 78,535, SEPT9 185,839, CCSA-3 216,434. 
Despite having lower sensitivity and speciﬁ city, the low-cost and minimally-invasive 
nature of these tests allow more frequent screening, resulting in better detection of 
early stage disease than with OC alone. CONCLUSIONS: Though currently there are
no blood-based biomarkers approved for early colorectal cancer screening, we can 
assess the expected impact of these tests once developed on colorectal cancer in the 
U.S. population. A complete sensitivity analysis of the sensitivity and speciﬁ city of a
hypothetical biomarker provides a map of cost-effectiveness within which any test
developed will fall.
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AN ECONOMIC EVALUATION OF CIRCULATING TUMOR CELLS
DETECTION IN METASTATIC BREAST CANCER
Rahman M1, Malone D2, Armstrong E2
1Ortho Clinical Diagnostics, Raritan, NJ, USA, 2University of Arizona, Tucson, AZ, USA
OBJECTIVES: Metastatic breast cancer (MBC) is a costly and burdensome disease in 
the United States. In 2008, an estimated 182,460 women will receive a new diagnosis
of breast cancer and 40,480 will die from the disease. The objective of this study was
to conduct a cost-effectiveness analysis of a diagnostic test for circulating tumor cells
(CTC) (CellSearch) plus imaging versus imaging alone. METHODS: This study used 
a probabilistic Markov cost-utility analysis based on a pivotal clinical trial evaluating 
the CellSearch technology. The perspective of the study was that of a managed care 
organization. The primary basis for estimates of transitions between health states were 
derived from the pivotal trial evaluating CellSearch. Using patient level data, transi-
tion probabilities were developed for patients with CTC counts of  5 or q5 over 3 
month intervals. The same approach was used for imaging studies where imaging was
classiﬁ ed as either regression or stable disease or progressive disease. Utility estimates
were obtained from the literature. The model took into account estrogen/progesterone 
receptor status as well as HER2 receptor status. Costs were based on Medicare fee
schedules or those reported in the literature. RESULTS: The mean number of Quality
Adjusted Life Years (QALYs) for imaging was 13.60 (SD  1.88) as compared to 15.32
(SD  1.44) for CellSearch plus imaging (p  0.05). The annualized treatment and
monitoring costs of using CellSearch plus imaging was higher than imaging alone 
($56,392 vs. $44,408, p  0.05). Cost-effectiveness acceptability curves indicated that 
CellSearch plus imaging had a higher probability of being cost-effective than imaging 
alone when willingness to pay per QALY exceeded $7,500. CONCLUSIONS: This
analysis suggests that CellSearch combined with imaging may be a cost-effective 
strategy for monitoring patients with MBC. The additional cost of the technology 
relative to the additional gains in QALYs falls well below commonly cited thresholds
for accepting new technologies.
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COST-EFFECTIVENES ANALYSIS OF DOCETAXEL VERSUS
STANDARD REGIMEN AS THE INDUCTION CHEMOTHERAPY 
OF LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL
CARCINOMA IN POLAND
Walczak J1, Lasota K1, Malczak I1, Pawlik D1, Semeniuk A1, Simon A1, Bryl M1, Lis J2, Nogas G1
1Arcana Institute, Cracow, Poland, 2Sanoﬁ  – Aventis sp. z o.o, Warsaw, Poland
OBJECTIVES: To conduct a cost effectiveness analysis (CEA) of docetaxel plus cis-
plastin and 5-ﬂ uorouracil (TPF) vs cisplastin and 5-ﬂ uorouracil (PF) as induction
chemotherapy followed by concurrent chemoradiation (RCT TAX 324) or radiation
therapy (RCT TAX 323) in locally advanced unresectable head and neck squamous 
cell carcinoma (HNSCC) in Poland. METHODS: We constructed two cost-effective-
ness Markov models (basing on TAX 324 or TAX 323) which include four health
states: stable, response, progression and death. The CEA was conducted from both
payers’ perspective (National Health Fund and patient), using clinical data from pub-
lished sources, Polish cost data and a 15-year time horizon and annual discount rate
of costs and beneﬁ ts at 5%. RESULTS: Based on a systematic review two randomized
clinical trials were included in the comparison TAX 323 and TAX 324. Average costs 
of the treatment for HNSCC (including chemotherapy, radiation or chemoradiation
therapy, treatment of serious adverse events, surgery, health state monitoring, relapse 
treatment and palliative care) were: PLN54,708 for TPF and PLN40,614 for PF basing 
on TAX 324 and PLN46,107 for TPF and PLN27,510 for PF basing on TAX 323.
Basing on TAX 324 treatment effects (per patient) were 4.3631 LYG vs. 3.4183 LYG 
respectively for TPF and PF regimens. Basing on TAX 323 treatment effects (per 
patient) were 1.9694 LYG for TPF vs. 1.6875 LYG for PF. ICER for the TPF vs. PF
comparison for trial TAX 324 was PLN14,916.40/LYG and PLN65,958.51/LYG for
trial TAX 323. CONCLUSIONS: The docetaxel regimen is more effective and more
expensive in the induction treatment of patients with locally advanced unresectable 
HNSCC compared with PF chemotherapy. ICERs are below the acceptable threshold, 
therefore the docetaxel therapy can be considered a cost-effective treatment for locally 
advanced unresectable HNSCC in Poland.
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COST-EFFECTIVENESS ANALYSIS OF LUNG CANCER SCREENING 
WITH COMPUTED TOMOGRAPHY
Chien CR1, Chen THH2
1China Medical University Hospital, Taichung, Taiwan, 2National Taiwan University Hospital, 
Taipei, Taiwan
OBJECTIVES: Given a high cost again high incidence of lung cancer lung cancer 
screening with Computed Tomography (CT) is a debatable issue within medical com-
munity. METHODS: We performed a health economic analysis via computer simula-
tion to track the annual transition among ﬁ ve health states (disease free, preclinical 
disease, local disease with treatment, advanced lung cancer, and death) with a proba-
bilistic Markov model. The primary scenario mimics that of the Dutch-Belgian ran-
domised lung cancer multi-slice CT screening trial (NELSON) study. The primary
endpoint was the incremental cost- effectiveness and cost-utility (quality-adjusted life 
year, QALY) ratio (ICER and ICUR). Model parameters were derived from literatures. 
Model validation on stage-speciﬁ c case ﬁ nding, survival rate, and treatment related
cost were simulated and compared with literatures. RESULTS: Model validation 
revealed comparable results between estimation and observation. In our primary sce-
nario, the mean ICER was 51,774 USD/LY. If 50,000 USD/LY was taken as the 
threshold of willingness to pay, there was 48% or so chance that CT screening will 
be cost-effective. When quality-of-life related health utility was taken into consider-
ation, the mean ICUR was 730,966 (USD/QALY). When other screening schedules
were simulated and compared, intensive screening (such as annual screening) is no 
cost-effective. CONCLUSIONS: Our simulation reveals that population-based lung 
cancer screening with CT is not cost -effective. This result provides an evidence for 
policy-makers on lung cancer screening before the results of randomized controlled 
studies available.
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A COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AT 
A TERTIARY CANCER CENTER
Miller LA, Lau J, Lal LS, Dacosta Byﬁ eld S, Arbuckle R
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
OBJECTIVES: This study evaluates the cost-effectiveness and budget impact of benda-
mustine, a recently approved alkylating mechlorethamine derivative for the treatment
of chronic lymphocytic leukemia (CLL), as part of the Formulary Management System
at a major tertiary cancer center in the United States. METHODS: Decision analytical 
models were developed to estimate the cost-effectiveness of bendamustine in CLL
patients receiving either ﬁ rst-line or salvage therapy. The ﬁ rst-line model compared 
bendamustine alone versus a combination therapy of ﬂ udarabine, cyclophosphamide,
and rituximab (FCR). The salvage model also compared bendamustine alone to the
same FCR combination for CLL therapy. The outcome of interest was progression-free
life years (PFLY), based on published literature and clinical use estimates. Direct
institutional medical costs for a one-year time period were utilized. In addition, a 
budget impact analysis was also conducted for adding bendamustine to the Formulary. 
RESULTS: Bendamustine is more convenient – only a single infusion is required 
compared to multiple infusions for the FCR combination. However, based on outcome 
estimates from literature and the application of the institutional costs, bendamustine
was found to be less costly and also less effective. The cost per PFLY saved by using
the FCR combination for treatment of CLL for ﬁ rst-line therapy was $2964. The cost 
was $5553 per PFLY saved for the same FCR combination for the treatment of CLL 
in salvage therapy. The budget impact model showed that the institution will utilize 
about $6.43 million worth of bendamustine annually based on acquisition costs and 
estimated usage. CONCLUSIONS: Bendamustine appears to be less cost-effective than 
other therapeutic regimens for the treatment of CLL. Bendamustine was added to the 
Formulary as a second- or third-line option for both model indications. Future eco-
nomic analyses will be conducted to determine how closely the current economic
model predicts actual utilization and cost-effectiveness at the institution.
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EVIDENCE SYNTHESIS FOR MODELING THE NATURAL HISTORY OF 
ANAL PENILE AND OROPAHRYNGEAL CANCERS
Abimbola T, Craig BM, Rollison D, Kumar A, Giuliano A
Mofﬁ tt Cancer Center, Tampa, FL, USA
OBJECTIVES: Substantial evidence on the increased incidence of HPV-associated 
malignancies is mounting as a result of on-going natural history studies on HPV 
infections as well as vaccination trials. Yet, there remains a paucity of results from
